Plain-English translation of NCT03036813 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Sickle cell disease research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial tested , a new oral medication designed to help people with sickle cell disease by improving how oxygen is carried in the blood. The study compared the medication at two different doses against a placebo (a dummy pill with no active ingredient) to see if it could reduce the number of painful crises and improve overall health in people aged 12 to 65.
Sickle cell disease causes severe pain crises that can land people in the hospital, and there is a need for new treatments that can reduce how often these crises happen. This trial tested whether this medication could offer a better way to manage the condition and improve quality of life.
Participants were randomly assigned to receive either one of two doses of the medication or a placebo, taken orally by mouth. The study was double-blind, meaning neither the participants nor the researchers knew who was receiving the active medication versus placebo. Participants attended multiple visits over the study period to have their blood checked, report any pain crises, and discuss how they were feeling on the treatment.
AI-generated summary from trial data · Oct 12, 2026 · Not medical advice
United States